Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Saeed Ahmed

Gastroenterology Wesley Chapel, FL Medical Doctor

NPI 1235228776 CMS profile 328617

2050 Ashley Oaks Cir Ste 102, Wesley Chapel, FL 33544

Open in the dashboard

General payments

$14,201

653 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$15,700 paid to institutions, not to them · program year 2023

Through program year 2025, Saeed Ahmed of Wesley Chapel, FL is reported in the CMS Open Payments database as having received $14,201 across 653 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $15,700 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,832 189
2024 General $3,895 138
2023 General $2,898 130
2022 General $1,233 58
2021 General $1,139 66
2020 General $561 33
2019 General $644 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Saeed Ahmed
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Saeed Ahmed were reported at $3,832. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Saeed Ahmed Gastroenterology median Middle half National median
2019 $644 $417 $126–$1,100 $163
2020 $561 $224 $74–$624 $114
2021 $1,139 $352 $106–$1,054 $132
2022 $1,233 $448 $129–$1,270 $149
2023 $2,898 $533 $150–$1,390 $160
2024 $3,895 $605 $160–$1,606 $164
2025 $3,832 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,098 174 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,923 125 payments
  3. Janssen Biotech, Inc. $844 36 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $815 44 payments
  5. Medtronic, Inc. $799 11 payments
  6. Olympus America Inc. $764 4 payments
  7. Pfizer Inc. $583 33 payments
  8. Celgene Corporation $582 40 payments
  9. Lumendi LLC $453 1 payment
  10. Ardelyx, Inc. $388 27 payments
  11. Other $3,952 158 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,827 644 payments
  2. Travel and Lodging $1,217 5 payments
  3. Education $134 3 payments
  4. Consulting Fee $24 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,644 102 payments
  2. LINZESS $1,150 65 payments
  3. RINVOQ $1,008 59 payments
  4. EVIS X1 VIDEO SYSTEM CENTER $764 4 payments
  5. CREON $759 43 payments
  6. SKYRIZI $693 37 payments
  7. ZEPOSIA $621 37 payments
  8. STELARA $560 21 payments
  9. EndoFlip $535 5 payments
  10. XELJANZ $497 28 payments
  11. Other $9,362 444 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

2,074

Median for Gastroenterology: 569

Drug cost

$1,456,820

Median for Gastroenterology: $104,976

Branded share of claims

37.3%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 11 $272,902
Humira(Cf) Pen Adalimumab Brand 36 $242,364
Rinvoq Upadacitinib Brand 21 $230,884
Xifaxan Rifaximin Brand 64 $198,987
Linzess Linaclotide Brand 156 $175,261
Humira(Cf) Adalimumab Brand 11 $72,793
Ibsrela Tenapanor Hcl Brand 23 $71,065
Relistor Methylnaltrexone Bromide Brand 20 $46,038
Trulance Plecanatide Brand 28 $24,774
Lialda Mesalamine Brand 17 $16,996

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$156,607

Medicare's payments for the services billed

Medicare patients

473

Average age 74

Services billed

1,862

266 women, 207 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 45%
Diabetes 39%
Chronic kidney disease 38%
Atrial fibrillation 28%
Depression 28%
Heart failure 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $281
$281 64 —
SKYRIZI
  • AbbVie, Inc. $272
$272 — —
RINVOQ
  • AbbVie, Inc. $239
$239 21 —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $139
$139 — —
IBSRELA
  • Ardelyx, Inc. $122
$122 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

653 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record